Cancer
Commented by Nico Popp on October 6th, 2026 | 07:35 CEST
Fighting Skin Cancer: How Vidac Pharma, Biofrontera and Regeneron Target Different Stages
At the recent annual meeting of the European Academy of Dermatology and Venereology in Vienna, the focus was on new approaches to treating extensive skin damage. The fight against skin cancer is shifting: It is no longer just about combating developed tumors, but about stopping the disease before it breaks out. Destroying diseased cells early on spares patients from major surgeries and eases the burden on the healthcare system. We present the latest developments and opportunities for investors.
Read
Commented by Jens Castner on September 28th, 2026 | 07:10 CEST
WHEN STOCK PRICES AND REALITY COLLIDE: THE WEEK OF TRUTH FOR BYD, VIDAC PHARMA AND FEDEX
This week holds a fascinating lesson for investors. BYD, Vidac Pharma and FedEx, three publicly traded companies that could hardly be more different, are holding their annual shareholder meetings: a Chinese auto giant, a British-Israeli biotech minnow, and an American logistics conglomerate. Current developments reflect three completely different realities. The spectrum ranges from global market battles to controversial issues regarding insider stock sales and executive compensation. Two of the stocks have recently lost about half their value. The third, while down significantly from its all-time high after a record run, is still clearly up for the year. Read on to learn about the opportunities and risks this presents.
Read
Commented by Nico Popp on September 25th, 2026 | 07:50 CEST
Breakthroughs in Skin Cancer Treatment: New Approaches from Biofrontera and Moderna – Vidac Pharma Faces a Busy Fall
For a long time, the treatment of skin cancer and its precancerous stages resembled a makeshift compromise: Doctors used scalpels, froze affected areas, or prescribed aggressive creams that destroyed tissue. It was not uncommon for patients to suffer pain and weeks of delayed wound healing. But a completely new dynamic is currently emerging in the sector. Suddenly, innovations involving light beams, messenger RNA (mRNA), and the metabolic reprogramming of cancer cells are making headlines. We present the latest developments in skin cancer and its precancerous stages. The race for innovation has only just begun.
Read
Commented by Carsten Mainitz on September 15th, 2026 | 10:30 CEST
New Approaches to Fighting Cancer: Why Vidac Pharma, BioNTech and Evotec Deserve Attention
Cancer cells use sophisticated defence mechanisms to evade the immune system and reprogram their own metabolism. These mechanisms are now increasingly being targeted by biotech companies. BioNTech has more than EUR 16 billion in cash and is driving the next generation of immunotherapies. Evotec is scaling up drug development through strong alliances but has eroded investor confidence. This skepticism is weighing on its share price. Developments at Vidac Pharma are particularly exciting. The company focuses on the metabolic reprogramming of malignant cells. Results from a potentially groundbreaking Phase 2b trial are imminent. Which approach offers the greatest promise?
Read
Commented by Fabian Lorenz on August 31st, 2026 | 06:45 CEST
Shock at BioNTech! Insider Buying at Nordex! Comeback Story for dynaCERT!
Could dynaCERT become the comeback story of the year? Analysts at GBC Research certainly believe the cleantech stock could rise to EUR 0.48. The shares are currently trading at EUR 0.06. The company's German management team is working hard to engineer a comeback. In particular, it has recently celebrated successes in commercializing its technology in Vietnam and Mexico. Further positive news should follow in the coming months. BioNTech, on the other hand, shocked its shareholders with Friday's announcement. The Phase 2 trial of its cancer immunotherapy candidate for colorectal cancer has been halted. Does this mean the mRNA race against Moderna is lost? The Nordex share has also recently lost momentum. The stock has been moving sideways since February. But now an insider purchase is attracting attention. Not all analysts, however, share the optimism.
Read
Commented by Matthias Schomber on August 24th, 2026 | 08:20 CEST
Cancer Breakthrough and Defense Boom: BioNTech and Moderna Take Off! Can Volatus Aerospace Follow Suit?
In the capital markets, two entirely different future-oriented industries are simultaneously stepping into the spotlight. While in the biotech sector, hopes for groundbreaking cancer therapies are fueling a massive comeback for companies such as Moderna and BioNTech, a highly exciting turnaround candidate may be emerging in the specialized field of unmanned aviation. Investors are rightly asking themselves whether the recent optimism surrounding biotech stocks is underpinned by fundamental strength or whether it is merely a short-lived flash in the pan followed by a sell-off. Those who can now read the right signals in financial data and chart patterns may be able to identify which stocks are poised for the next major trend movements. We take a closer look for you.
Read
Commented by Stefan Feulner on August 24th, 2026 | 07:50 CEST
Merck, Vidac Pharma, Moderna: New Cancer Treatments Send Stock Markets Soaring
A breakthrough in cancer research sent the stock market into a frenzy last week. For the first time, a personalized mRNA therapy has achieved key endpoints in a large Phase 3 trial, adding billions in market value within hours. At the same time, smaller biotech companies are working on entirely different approaches to target tumors at one of their greatest vulnerabilities. The race for the next generation of cancer treatments is thus gaining momentum. The economic potential is enormous.
Read
Commented by Tarik Dede on August 17th, 2026 | 07:55 CEST
Cancer in Focus: Merck & Co., Vidac Pharma and AstraZeneca
According to the International Agency for Research on Cancer (IARC), part of the WHO, there are currently around 20.6 million new cancer cases worldwide. The annual death toll is estimated at approximately 10 million people. In recent years, more than 53 million people globally have received a cancer diagnosis. According to the WHO, the number of new cases per year is expected to rise to about 35 million by 2050. Two factors are generally cited as the main drivers: demographic change, with the global population getting older, as well as rising rates of obesity, physical inactivity, smoking and air pollution in many countries. Unsurprisingly, the oncology market is correspondingly lucrative. Oncology is the world's largest pharmaceutical market. There is, however, also some good news: the age-adjusted risk of dying from cancer is declining thanks to earlier detection, targeted therapies and advances in immuno-oncology. Today, we take a closer look at this market through the stocks of Merck & Co., Vidac Pharma and AstraZeneca.
Read
Commented by Tarik Dede on August 11th, 2026 | 07:20 CEST
Pharma and Biotech Stocks in the Spotlight: Moderna, BioNxt Solutions, and Eli Lilly
Many patents held by the major pharmaceutical giants are set to expire in the coming years. Once that protection is gone, companies face the risk of lost revenue due to copycat drugs, known as generics. Consequently, the stakes are currently very high in the industry. Acquisitions and massive investments in the research pipeline are shaping the landscape. The markets for oncology and weight-loss injections are particularly lucrative. The former is a matter of life and death, while the latter is mostly about appearance and health. At the same time, many countries need to reduce their healthcare costs. Demographic trends and many lifestyle-related diseases are taking their toll on people and health insurance premiums. For investors, this tension presents a wealth of opportunities. We are therefore taking a look today at the stocks of Moderna, BioNxt Solutions, and Eli Lilly.
Read
Commented by André Will-Laudien on August 4th, 2026 | 09:10 CEST
"Buy the Dip" in the Life Sciences Supercycle: Gerresheimer, Vidac Pharma, Novo Nordisk, and Pfizer as Top Performers of the Future
Rising healthcare spending, an aging population, and an unprecedented depth of research are propelling the life sciences sector into a multi-year supercycle. And there are some strong players! Gerresheimer stands out as a brilliant infrastructure asset and a leading provider of high-quality primary packaging. In the field of injections and biologics, the company benefits directly from the explosion of complex therapies and GLP-1 markets. Vidac Pharma is conducting research in the field of cancer and leveraging the Warburg effect for its upcoming studies—a classic high-beta play for investors betting on above-average growth. Novo Nordisk remains the undisputed flagship of the obesity and diabetes wave, and Pfizer is using the current lull in valuations as an opportunity to ignite the next phase of growth with a broad pipeline spanning oncology, vaccines, and new forms of therapy. Who belongs in the portfolio for the next life sciences boom?
Read